Transforming growth factor-β1 and its receptors in patients with ulcerative colitis

International Immunopharmacology

Volumn 9, Issue 6, 2009, Pages 761-766

  Stadnicki, Antoni ^a,b   Machnik, Grzegorz ^a   Klimacka Nawrot, Ewa ^a   Wolanska Karut, Anna ^a   Labuzek, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b St Barbara Hospital   (Poland)

Author keywords

Immunohistochemistry; TGF receptors; TGF 1; Ulcerative colitis

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; MALE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECTUM; SIGMOID; TISSUE DISTRIBUTION; ULCERATIVE COLITIS;

ADULT; COLITIS, ULCERATIVE; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1;

EID: 67349222177     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.02.014     Document Type: Article

References (41)

1. Rahimi R., Nikfar S., and Abdollahi M. Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids. Med Sci Monit 13 (2007) PI13-PI18
2. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 347 (2002) 417-429
3. Baumgart D.C., and Carding S.R. Inflammatory bowel disease: cause and immunobiology. Lancet 369 (2007) 1627-1640
4. Jahanshahi G., Motavasel V., Rezaie A., Hashtroudi A.A., Daryani N.E., and Abdollahi M. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci 49 (2004) 1752-1757
5. Rahimi R., Nikfar S., Rezaie A., and Abdollahi M. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci 52 (2007) 2920-2925
6. Dieckgraefe B.K., Korzenik J.R., and Anant S. Growth factors as treatment options for intestinal inflammation. Ann N Y Acad Sci 1072 (2006) 300-306
7. Clavel T., and Haller D. Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: implications for chronic inflammation. Inflamm Bowel Dis 13 (2007) 1153-1164
8. Pepper M.S. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 8 (1997) 21-43
9. Stadnicki A., and Colman R.W. Hemostasis in inflammatory bowel diseases: current data and literature review. In: Keuusch G.T., and Kawakami M. (Eds). Cytokines, cholera and gut (1997), Amsterdam IOS Press 143-151
10. Stadnicki A., Kloczko J., Nowak A., and Sierka E. Alterations of haemostasis parameters with special reference to factor XIII and fibronectin in patients with ulcerative colitis. Eur J Enterogastrol Hepatol 4 (1992) 743-746
11. Suzuki R., Toda H., and Takamura Y. Dynamics of blood coagulation factor XIII in ulcerative colitis and preliminary study of the factor XIII concentrate. Blut 59 (1989) 162-164
12. Blobe G.C., Schiemann W.P., and Lodish H.F. Role of transforming growth factor beta in human disease. N Engl J Med 342 (2000) 1350-1358
13. Dignass A.U., and Podolsky D.K. Epithelial restitution and intestinal repair. In: Sartor R.B., and Sandborn W.J. (Eds). Kirsner's inflammatory bowel diseases (2004), Saunders, Philadelphia 18-29
14. Monteleone G., Kumberova A., Croft N.M., McKenzie C., Steer H.W., and MacDonald T.T. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 108 (2001) 601-609
15. Sanderson N., Factor V., Nagy P., Kopp J., Kondaiah P., Wakefield L., et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A 92 (Mar 28 1995) 2572-2576
16. Lawrance I.C., Maxwell L., and Doe W. Inflammation location, but not type, determines the increase in TGF-beta1 and IGF-1 expression and collagen deposition in IBD intestine. Inflamm Bowel Dis 7 (2001) 16-26
17. Di Mola F.F., Friess H., Scheuren A., Di Sebastiano P., Graber H., Egger B., et al. Transforming growth factor-betas and their signaling receptors are coexpressed in Crohn's disease. Ann Surg 229 (1999) 67-75
18. Göke M., Zuk A., and Podolsky D.K. Regulation and function of extracellular matrix intestinal epithelial restitution in vitro. Am J Physiol 271 (1996) 729-740
19. Souza R.F., Lei J., Yin J., Appel R., Zou T.T., Zhou X., et al. A transforming growth factor beta 1 receptor type II mutation in ulcerative colitis-associated neoplasms. Gastroenterology 112 (1997) 40-45
20. Grady W.M., Rajput A., Myeroff L., Liu D.F., Kwon K., Willis J., et al. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 58 (1998) 3101-3104
21. Kulkarni A.B., Huh C.G., Becker D., Geiser A., Lyght M., Flanders K.C., et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 90 (1993) 770-774
22. Truelove S.C., and Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 2 (1955 29) 1041-1048
23. Baron J.H., Connell A.M., and Lennard-Jones J.E. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1 (1964) 89-92
24. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162 (1987) 156-159
25. Ponchel F., Toomes C., Bransfield K., Leong F.T., Douglas S.H., Field S.L., et al. Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol 3 (2003) 18
26. Stadnicki A., Pastucha E., Nowaczyk G., Mazurek U., Plewka D., Machnik G., et al. Immunolocalization and expression of kinin B1R and B2R receptors in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 289 (2005) 361-366
27. Devani M., Cugno M., Vecchi M., Ferrero S., Di Berardino F., Avesani E.C., et al. Kallikrein-kinin system activation in Crohn's disease: differences in intestinal and systemic markers. Am J Gastroenterol 97 (2002) 2026-2032
28. Chowdhury A., Fukuda R., and Fukumoto S. Growth factor mRNA expression in normal colorectal mucosa and in uninvolved mucosa from ulcerative colitis patients. J Gastroenterol 31 (1996) 353-360
29. Babyatsky M.W., Rossiter G., and Podolsky D.K. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 110 (1996) 975-984
30. McCaffrey T.A., Du B., Consigli S., Szabo P., Bray P.J., Hartner L., et al. Genomic instability in the type II TGF-beta1 receptor gene in atherosclerotic and restenotic vascular cells. J Clin Invest 100 (1997) 2182-2188
31. Ying W.Z., and Sanders P.W. The interrelationship between TGF-beta1 and nitric oxide is altered in salt-sensitive hypertension. Am J Physiol Renal Physiol 285 (2003) F902-908
32. Li B., Khanna A., Sharma V., Singh T., Suthanthiran M., and August P. TGF-beta1 DNA polymorphisms, protein levels, and blood pressure. Hypertension 33 (1999) 271-275
33. Fuss I.J. The role IL-13 and the IL-13Rα2 in experimental and human ulcerative colitis. International Congress Center, mechanisms of intestinal inflammation, October 9-10 (2007) Dresden. Abs:20
34. Ohtani H., Kagaya H., and Nagura H. Immunohistochemical localization of transforming growth factor-beta receptors I and II in inflammatory bowel disease. J Gastroenterol 30 (1995) 76-77
35. Stallmach A., Schuppan D., Riese H.H., Matthes H., and Riecken E.O. Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease. Gastroenterology 102 (1992) 1920-1929
36. Wiercińska-Drapalo A., Flisiak R., and Prokopowicz D. Effect of ulcerative colitis activity on plasma concentration of transforming growth factor beta1. Cytokine 14 (2001) 343-346
37. Sambuelli A., Diez R.A., Sugai E., Boerr L., Negreira S., Gil A., et al. Serum transforming growth factor-beta1 levels increase in response to successful anti-inflammatory therapy in ulcerative colitis. Aliment Pharmacol Ther 14 (2000) 1443-1449
38. Rezaie A., Khalaj S., Shabihkhani M., Nikfar S., Zamani M.J., Mohammadirad A., et al. Study on the correlations among disease activity index and salivary transforming growth factor-beta 1 and nitric oxide in ulcerative colitis patients. Ann N Y Acad Sci 1095 (2007) 305-314
39. Fong C.Y., Pang L., Holland E., and Knox A.J. TGF-beta1 stimulates IL-8 release, COX-2 expression, and PGE(2) release in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 279 (2000) 201-207
40. Duvernelle C., Freund V., and Frossard N. Transforming growth factor-beta and its role in asthma. Pulm Pharmacol Ther 16 (2003) 181-196
41. Bayer E.M., Herr W., Kanzler S., Waldmann C., Meyer-Zum-Buschenfelde K.H., Dienes H.P., et al. Transforming growth factor-beta1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity. J Hepatol 28 (1998) 803-811